DUBLIN, Ireland, and Hørsholm, Denmark, 04 June, 2019: ERS Genomics Limited and Bioneer A/S today announced the signing of a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark based life science research and technology provider, will utilize CRISPR/Cas9 technology to generate a range of innovative human cell based disease models.

Under the terms of the license, Bioneer is able to generate and commercialize CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.

Eric Rhodes, CEO of ERS Genomics, said:Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."

“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.stated Lars H. Pedersen, CEO of Bioneer. Christian Clausen, CSO of Bioneer continues:Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models. ”

Financial details of the agreement were not disclosed.

Media contact:

For ERS Genomics:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947

For Bioneer A/S:
Lovisa Sunesson
Tel: +45 45160444

About ERS Genomics

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit

About Bioneer A/S

Bioneer A/S offers research-based services in the pharmaceutical, biotech and medical technology fields. Bioneer is a not-for-profit organization and a subsidiary of the Technical University of Denmark (DTU) and is approved by the Danish Ministry of Science and Technology as an authorised provider of technological services – a GTS entity,  to provide Danish companies local access to advanced high-tech services. Bioneer's services include protein production, drug formulation and characterization, molecular histology and detection, and human cell-based modeling of disease. Bioneer excels at combining methods from a diverse toolbox of technologies. Bioneer participates in a number of research collaborations with national and international research institutions and companies.